BLOGGERS: MARK SCHOLZ, MD & RALPH H. BLUM

The co-authors of Invasion of the Prostate Snatchers, blog alternate posts weekly. We invite you to post your comments.
Showing posts with label Peter Grimm. Show all posts
Showing posts with label Peter Grimm. Show all posts

Tuesday, February 23, 2016

Memorials: Peter Grimm, MD and Jay Cohen, MD

BY MARK SCHOLZ, MD

I am sad to report the passing of two giant contributors in the prostate cancer realm, Dr. Peter Grimm and Dr. Jay Cohen. 

Dr. Grimm was the Director of the Prostate Cancer Center of Seattle which pioneered seed implantation for prostate cancer. He was instrumental in establishing the Seattle Prostate Institute in 1997. Along with his colleagues, Dr. John Blasko and Dr. Haken Ragde, he trained over 6000 physicians worldwide in how to administer seed implants. Their team has treated over 10,000 patients since 1985. Over one thousand centers now perform seed implantation, which is now a treatment of choice for many men with prostate cancer.   Dr. Grimm completed his graduate training in radiation oncology at UCLA. 


Dr. Grimm’s technical endeavors, such as the development of six US patented devices, have led to continuous improvements in the equipment widely used in prostate brachytherapy. He has served as one of fifteen physicians on the Medicare Practicing Physicians Advisory Board in Washington DC and served on the American Society of Therapeutic Radiation Oncology economic committee. He was the CEO of ProQura, and served on advisory boards for many seed implant companies. As lead editor, Dr. Grimm and members of the Prostate Cancer Results Study Group published a collaborative book on prostate cancer, The Prostate Cancer Treatment Book. His curriculum vitae included over 80 scientific articles and book chapters on prostate cancer.  


Dr. Grimm received an Outstanding Achievement awards from the American Brachytherapy Society, Midwestern University, and the Northwest Osteopathic Foundation. Born and raised in Seattle, he had a lifelong passion for preserving wild salmon. He was a board member of Long Live the Kings, a non-profit organization dedicated to preserving wild salmon in the Northwest. In a cooperative effort with the Hood Canal Salmon Enhancement Group and Washington State Department of Wildlife, he has released over 3 million wild salmon.  He also serves as a board member for Pacific Northwest College. He leaves behind his spouse Dawn Winters, PhD and two children, Robyn Vera, DO a radiation oncology physician in Olympia Washington and Justin Grimm, an IT specialist.


I am also saddened to report that Dr. Jay S. Cohen passed away in December 2015. My interactions with Dr. Cohen were related to his excellent book on prostate cancer: Prostate Cancer Breakthroughs. However, outside of the prostate cancer world, his researching and writing skills were eclectic and broad. Among his many and varied interests were his extensive research on the causes of medication side-effects. He published his findings in eight books, leading medical journals, and articles and publications such as Newsweek, Bottom Line Health, The New York Times, The Washington Post, Consumer Reports, Wall Street Journal. Another of his books, Over Dose: The Case Against the Drug Companies was favorably reviewed by the Journal of the American Medical Association.  Dr. Cohen was an Adjunct Associate Professor of Psychiatry and the Chairman of the Medical Advisory Committee of the Erythromelalgia Association, and a Fellow of the American College of Nutrition. He lived in Del Mar, CA for over 40 years. He is survived by his son Rory Cohen and daughter-in-law Alana Cohen, and a nephew, Hal Cohen.

Tuesday, September 15, 2015

2015 Conference Recap

BY MARK SCHOLZ, MD

Every year’s Conference presents recurring themes.  This year’s focus was prevention, combination treatment and timeliness were emphasized. We live in an era of exploding technological progress. It is a delightful problem to have a wealth of new treatment options and diagnostic tools.  However, just like buying a new car or a new smart phone, it takes a little time to learn the ropes and fully exploit the complete range and capabilities of the new technology.  A short blog can’t cover everything from a three-day conference.  Here are a few comments.
 
Dr. Dan Margolis, an expert on prostate imaging from UCLA, presented information on 3 Telsa, multi-parametric MRI’s capacity as a substitute for random needle biopsy in men with elevated PSA who have never been previously diagnosed with prostate cancer.  MRI offers the advantage of being equally or more accurate than random biopsy without relying on invasive techniques.
 
Dr. Chuck Drake, from John Hopkins, the preeminent expert in the world on immune therapy for prostate cancer, presented exciting data on how many of the new immune drugs work synergistically when given in combination.  “Synergism” means that when either drug is given by itself the anticancer effect is rather modest.  But when the two drugs are given in combination, the anticancer effect is multiplied.  Provenge has already been FDA approved for prostate cancer.  Hopefully Yervoy will also be an approved indication for prostate cancer in the next six to 12 months.  The combination of these two drugs together offers immense hope for jumpstarting immunologic treatment for prostate cancer.
 
Dr. John Mulhall, the expert in the world on sexuality and prostate cancer from Memorial Sloan Kettering, spent a lot of time emphasizing mindfulness in the selection of treatment. In other words, he was saying that it is better to minimize damage by selecting the least toxic form of prostate cancer treatment than trying to fix an already established problem.
 
Dr. Peter Grimm, sometimes called “The Father of Seed Implant Therapy,” delivered a candid overview of the world of radiation therapy, emphasizing the improved cure rates and reduced toxicity seed implant therapy offers.  He also spoke on how increased financial incentives to do IMRT, Proton therapy and SBRT, distorts the decision making process and slants treatment away from seed implants.
 
This is only the briefest of overviews and no words can express all the fun and games that Dr. Mark Moyad injected into the proceedings. I can only say that initial feedback from the attendees was extremely positive.

2015 PCRI Conference DVDs, which include all the presentations, will be available in six weeks at a suggested donation of $150. For more information, email: info@pcri.org.  In addition, the PCRI will be presenting its second annual Mid-Year Update, March 26, 2016, an afternoon of educational sessions in developments in the prostate cancer world. Laurence Klotz, MD who has been called “The Father of Active Surveillance” will be one of the speakers. Learn more at: www.pcri.org/2016-mid-year-update

Tuesday, September 1, 2015

The September Prostate Cancer Conference

BY MARK SCHOLZ, MD

PCRI’s Prostate Cancer Conference for Patients is less than two weeks away.  The Conference is a unique event giving opportunity for patients to interact closely with experts in prostate cancer and leaders in research.  It is also a great venue to establish a connection with other patients who have “been there and done that.” This is a weekend to stay informed about the latest in prostate cancer.

That’s where the invited experts come in - we ask them to present their lectures in a way that can be understood by patients. This year’s program will stress breakthroughs in imaging, immunology, new hormone therapy, expanded roles for chemotherapy and the latest thinking on radiation.  The Saturday program will include:

 
·         Dr. Matthew Cooperberg from UCSF is providing an update on active surveillance .

·         Dr. John Mulhall from Memorial Sloan Kettering  will educate us on the latest methods for maintaining normal sexual function after treatment for prostate cancer.

·         Dr. Peter Grimm, from Prostate Cancer Center of Seattle, a world authority on seed implantation reviewing the latest breakthroughs in the area of radiation therapy.

·         Dr. William Oh from Mount Sinai will discuss breakthroughs in injectable radiation that targets bone metastases and new roles for chemotherapy.

·         Dr. Tomasz Beer from the University of Oregon will provide the latest thinking on the powerful new hormonal agents Xtandi and Zytiga.

·         Dr. Dan Margolis a world-renowned prostate imaging expert from UCLA will explain new used for multiparametric imaging of the prostate.

·         Dr. Charles Drake from Johns Hopkins, the world’s preeminent immune expert in prostate cancer will share the latest breakthroughs in this rapidly advancing field.

Dr. Mark Moyad, our moderator, will also be speaking about supplements and diet and how they can lead to increased survival and better quality of life. 

Cancer care is advancing so rapidly that it takes a team effort between you and your physician to achieve the best care.  For the average patient it is overwhelming to try to stay up to date with the latest clinical studies, journal articles and protocols. Often the best place for information is an event like this that specializes in distributing the latest information in a digestible format. 

On Sunday morning, most of our Saturday speakers will participate in a smaller group setting and review their presented topics.  The conference will end with a speaker roundtable to see what treatment the experts will recommend when confronted with actual patient situations. 

The PCRI Conference is for your empowerment. We want it to give you hope and a new confidence in facing the challenging tasks of making important treatment decisions that will impact you for the rest of your life.